The global anti-venom market size was estimated at USD 1.18 billion in 2023 and is expected to grow at a CAGR of 8.11% from 2024 to 2030. This growth is attributed to the rising prevalence of venom bites/stings, increasing awareness of anti-venom treatments, growing research initiatives to develop effective treatments, and growing government initiatives to spread. According to the World Health Organization (WHO), approximately 5.4 million people get bitten by snakes each year. Moreover, around 81 410 to 137 880 mortalities occur globally each year as a result of snake bites.
Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.
Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.
Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.
This product will be delivered within 2 business days.
Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.
Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.
Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.
Global Anti-venom Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the publisher has segmented the global anti-venom market report based on species, type, mode of action, end-use, and region:- Species Outlook (Revenue, USD Million, 2018 - 2030)
- Snake
- Common Cobra
- Common Krait
- Russell Viper
- Others
- Scorpion
- Spider
- Other Species
- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Polyvalent
- Monovalent
- Mode Of Action Outlook (Revenue, USD Million, 2018 - 2030)
- Cytotoxic
- Neurotoxic
- Haemotoxic
- Cardiotoxic
- Myotoxic
- Others
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Regional Outlook (Revenue in USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Anti-Venom Market Variables, Trends & Scope
Chapter 4. Anti-Venom Market: Species Estimates & Trend Analysis
Chapter 5. Anti-Venom Market: Type Estimates & Trend Analysis
Chapter 6. Anti-Venom Market: Mode of Action Estimates & Trend Analysis
Chapter 7. Anti-Venom Market: End Use Estimates & Trend Analysis
Chapter 8. Anti-Venom Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Bharat Serums and Vaccines Limited (BSV)
- Boehringer Ingelheim International GmbH
- Boston Scientific Corporation
- CSL Limited
- Haffkine Bio-Pharmaceutical Corporation Limited
- Incepta Pharmaceuticals Limited
- Merck & Co., Inc.
- Pfizer, Inc.
- MicroPharm Limited
- Rare Disease Therapeutics Inc.
- South African Vaccine Producers (Pty) Ltd.
- Medtoxin Venom Laboratories
- Instittue of Immunology
- Alomone Labs, Ltd.
- Sigma Aldrich
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.18 Billion |
| Forecasted Market Value ( USD | $ 2.02 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
